Analyst Insights

TG Therapeutics Is Poised For Upside, Says Roth Capital Analyst

In a research note released today, Roth Capital reiterated coverage on TG Therapeutics, Inc. (TGTX) with a Buy rating and a price target of $15.

Regeneron Has Solid Growth Prospects, Says Roth Capital Analyst

In a research note released this morning, Roth Capital reiterated coverage on Regeneron Pharmaceuticals (REGN) with a Buy rating and a price target of $382.00, following the announcement that …

Palatin Technologies Reiterated With A Buy At Roth Capital

In a research note issued this morning, Roth Capital reiterated coverage with a “Buy” rating on Palatin Technologies, Inc. (PTN) and a price target of $6.

Roth Capital Reiterates Buy Rating for Celator Pharmaceuticals

In a research note released this morning, Roth Capital reiterated coverage on Celator Pharmaceuticals, Inc (CPXX) with an Outperform rating and a price target of $15.00, which is based …

Restoration Hardware Holdings Shares Are Poised To Go Higher, Says William Blair

In a research note released this morning, William Blair reiterated coverage on Restoration Hardware Holdings, Inc. (RH) with an Outperform rating.

William Blair Maintains Outperform On BioDelivery Sciences

William Blair today maintained an Outperform rating on BioDelivery Sciences (BDSI) with $23.00 price target, which is derived through a net present value analysis …

William Blair Reiterates Outperform Rating For Dynavax

In a research note released this morning, William Blair reiterated coverage on Dynavax Technologies Corporation (DVAX) with an Outperform rating and a price target of …

Canaccord Raises Price Target On Medifast; Expects Improved Profitability

In a research note released today, Canaccord analyst Scott Van Winkle maintained his Hold position on Medifast (MED) and upgraded his price target to $32.00 from $31.

OraSure Technologies Price Target Raised at Canaccord Following Agreement With AbbVie

In a research note issued today, Canaccord analyst Mark Massaro reiterated a Buy rating and boosted his price target on OraSure Technologies (OSUR) to $11.00 …

Valeant Pharmaceuticals Reiterated With A Buy At Canaccord

In a research note issued today, Canaccord maintained coverage with a “Buy” rating on Valeant Pharmaceuticals (VRX), and a price target of $168.00 a share.